A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

Summary

A study of CM313 in subjects with systemic lupus erythematosus

Timeline

Start

2022-10-30

Primary completion

2023-10-30

Completion

2023-10-30

Publications

• Zhao J, Lin C, Xie Q, Shu Q, Cui Y, Luo H, Fan W, Huang A, Zhao Y, Fu Z, Xie C, Wu H, Yang N, He L, Feng P, Zhang T, Zhou H, Liu W, Hou Q, Mao X, Sun J, Chen B, Zeng X. Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib/IIa trial. Signal Transduct Target Ther. 2025 Nov 26;10(1):383. doi: 10.1038/s41392-025-02487-2.

Drugs

Indications